Index of 2004 Publications



1: Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004 Sep 15;22(18):3813-25.L
PMID: 15365079
Download PDF

2: Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, Leung SY, Yuen ST, Zhu S, Hernandez-Boussard T, Montgomery K, Nielsen TO, Patel RM, Goldblum JR, Heinrich MC, Fletcher JA, Van De Rijn M. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene. 2004 Aug 23
PMID: 15326474
Download PDF

3: Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 2004 Aug 10
PMID: 15304388
Download PDF

4: Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC. Synergistic Effect of SU11248 with Cytarabine or Daunorubicin on FLT3-ITD Positive Leukemic Cells. Blood. 2004 Aug 10
PMID: 15304385

Download PDF

5: Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, Corless CL, Demetri GD, Fletcher CD, Fletcher JA. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004 Aug 1;64(15):5127-31.
PMID: 15289315
Download PDF

6: Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crepineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mecheri S, Tursz T, Zitvogel L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004 Aug;114(3):379-88.
PMID: 15286804
Download PDF

7: Griswold IJ, Shen LJ, LaRosee P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW. Effects of MLN518, A Dual FLT3 and KIT Inhibitor, on Normal and Malignant Hematopoiesis.
Blood. 2004 Jul 8
PMID: 15242881
Download PDF

8: Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, Fletcher CD. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004 Jul;28(7):889-94.
PMID: 15223958
Download PDF

9: Heinrich MC, Corless CL. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for
molecular therapy of other sarcomas
. Cancer Treat Res. 2004;120:129-50. Review.
PMID: 15217222
PDF Not Available

10: West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004 Jul;165(1):107-13.
PMID: 15215166

Download PDF

11: Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr 15;103(8):2929-35. Epub 2004 Jan 08.
PMID: 15070666
Download PDF

12: Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 2004;22(1):106-16. Review.
PMID: 15069768
PDF Not Available

13: Heinrich MC. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects. Mini Rev Med Chem. 2004 Mar;4(3):255-71. Review.
PMID: 15032673
Download PDF

14: Hayes-Lattin B, Seipel TJ, Gatter K, Heinrich MC, Maziarz RT. Pure red cell aplasia associated with parvovirus B19 infection occurring late
after allogeneic bone marrow transplantation
. Am J Hematol. 2004 Mar;75(3):142-5.
PMID: 14978694
Download PDF

15: Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia. 2004 Apr;18(4):864-71.
PMID: 14973502
Download PDF

16: Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C, Niederwieser D, Druker BJ, Deininger MW. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Hematol J. 2004;5(1):55-60.
PMID: 14745431

17: Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC. KIT mutations are common in testicular seminomas. Am J Pathol. 2004 Jan;164(1):305-13.
PMID: 14695343
Download PDF